The High Stakes of Drug Pricing

This chapter explores the implications of capping prescription drug prices in the U.S. and how it contrasts with pharmaceutical practices in other countries. It discusses the potential risks to innovation and patient health outcomes, particularly in the context of cancer treatments and recent legislative changes. Additionally, the chapter delves into the cultural perceptions of pharmaceutical companies and the evolving relationship with regulatory bodies like the FDA.